sulfabenzamide is an approved drug (FDA (1945))
Compound class:
Synthetic organic
Comment: Sulfabenzamide is a sulfonamide antibacterial compound. It inhibits the bacterial dihydropteroate synthase pathway which generates the folic acid that is essential for bacterial growth.
|
|
No information available. |
Summary of Clinical Use ![]() |
The most common formulation of sulfabenzamide is in combination with sulfathiazole and sulfacetamide and is administered as a vaginal preparation (tablet or cream). The combined formulation was approved by the US FDA, but has since been discontinued. The drug may still be approved for use in other countries. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants [2]. The antibacterial MMOA is competitive inhibition of bacterial dihydropteroate synthase (DHPS) resulting in a block of folate biosynthesis [1]. |